Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Journal of Geriatric Oncology|April 3, 2026
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort studyJoosje C Baltussen, Jonathan E Knikman, Nienke A de Glas, et al.
Genome Medicine|August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYDJonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
Therapeutic Drug Monitoring|March 12, 2021
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical ToxicologyStein Bergan, Mercè Brunet, Dennis A Hesselink, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE StudyHenk-Jan Guchelaar, Cathelijne H van der Wouden, Lisanne E N Manson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U studyJonathan E Knikman, Mirjam de With, Niels Heersche, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Lancet (London, England)|February 4, 2023
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyJesse J Swen, Cathelijne H van der Wouden, Lisanne En Manson, et al.
Eclinicalmedicine|January 8, 2026
Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE studyVasileios Fragoulakis, Jesse J Swen, Margarita-Ioanna Koufaki, et al.
The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Pageof 15